- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer
During this segment, the panelists explore issues faced by managed care during treatment coverage decisions in castration-resistant prostate cancer (CRPC).
Michael Kolodziej, MD, discusses the high costs of newly developed agents, their role in drug-sequencing plans, and the Affordable Care Act’s impact on treatment coverage in CRPC.
Jeffrey D. Dunn, PharmD, MBA, explains the need for improvements in the research that can help provide better data about a drug’s effectiveness, and can help professionals determine a product’s cost and availability for health coverage.
David Quinn, MD, agrees with Dr Dunn and suggests that a patient’s improvements in health and overall outcomes must be additive to the cost of therapy. Dr Quinn further explains that by studying the value of agents used to treat CRPC, a paradigm shift may provide results about the benefits of options given to treat patients over a sequence of time.
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
